Those strategies, which are beyond the scope of this review to be discussed in detail, include therapies counteracting myeloid-derived suppressor cells (MDSCs), neutralization of tumor acidity, chemotherapy, inhibition of IDO, and treatment with antibodies against immune suppressive cytokines (243–248). The gene discussed is IDO1; the disease is neoplasm.